957211-19-7

Usage

Uses

Used in Pharmaceutical Industry:
1(2H)-Quinolineethanol, 3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-, (aS,2R)is used as a pharmaceutical compound for its potential interaction with biological targets. The presence of fluorine atoms and the quinoline ring may contribute to its activity as a drug candidate, possibly targeting specific receptors or enzymes in the body.
Used in Chemical Research:
In the field of chemical research, 1(2H)-Quinolineethanol, 3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-, (aS,2R)can be employed as a starting material or intermediate for the synthesis of other complex molecules. Its unique structure and functional groups make it a valuable tool for exploring new chemical reactions and developing novel compounds with specific properties.
Used in Material Science:
1(2H)-Quinolineethanol, 3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-a-(trifluoromethyl)-, (aS,2R)may also find applications in material science, where its fluorine-containing and aromatic structures could be utilized to create new materials with specialized properties, such as enhanced stability, chemical resistance, or specific interactions with other molecules.

Upstream product

• 359-41-1 1,1,1-trifluoro-2,3-epoxypropane 
• 957211-47-1 2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-5-(3-trifluoromethoxy-phenyl)-1,2,3,4-tetrahydro-quinoline 
• 130025-34-2 (S)-2-trifluoromethyl-oxirane 

Relevant academic research and scientific papers

Regio- and diastereoselective ring-opening of (S)-(-)-2-(trifluoromethyl) oxirane with chiral 2,5-disubstituted tetrahydroquinolines in hexafluoro-2-propanol

Multi-hundred grams of (S)-1,1,1-trifluoro-3-{(R)-2-[3-(1,1,2,2- tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-3,4-dihydroquinolin- 1(2H)-yl}propan-2-ol, a potent cholesteryl ester transfer protein (CETP) inhibitor, was prepared in quantitative isolated yield (>99%) with excellent chemical (>99% HPLC area%) and optical (>99% de) purities. The cornerstone to these results were achieved by regiospecific and diastereoselective ring-opening of optically pure (S)-(-)-2-(trifluoromethyl)oxirane (>99% ee) with (R)-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]- 1,2,3,4-tetrahydroquinoline (>99% ee) in hexafluoro-2-propanol at 22 °C for 24 h. This reaction did not require a rare earth metal salt (Yb(OTf) 3) as the catalyst nor a column chromatography for the purification. The excess (S)-(-)-2-(trifluoromethyl)oxirane and the solvent hexafluoro-2-propanol were recovered by distillation from the reaction and reused.

An efficient and scalable synthesis of (2R,αS)-3,4-dihydro-2-[3-(1,1, 2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-α- (trifluoromethyl)-1(2H)-quinolineethanol: A potent CETP inhibitor

An efficient and scalable synthesis of the potent CETP inhibitor, (2R,αS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl] -5-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-1(2H) -quinolineethanol 1, is described. One of the important intermediates,

Improved asymmetric synthesis of 3,4-dihydro-2-[3-(1,1,2,2- tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-α- (trifluoromethyl)-1(2H)-quinolineethanol, a potent cholesteryl ester transfer protein inhibitor

The asymmetric synthesis of 3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy) phenyl]-5-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-1(2H) -quinolineethanol (compound 11), a cholesteryl ester transfer protein inhibitor, Is accomplished. The asymmetric cent

Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform

Tetrahydroquinoline A is a potent inhibitor of the cholesterol ester transfer protein (CETP), a target for the treatment of low HDL-C and atherosclerosis. Low HDL-C has been identified as a key risk factor for cardiovascular disease in addition to high LD

Design, synthesis, and biological evaluation of (2R,αS)-3,4-dihydro- 2-[3-(1,1,2,2-tetrafluoroet-hoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl] -a-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibi

With the goal of identifying a CETP inhibitor with high in vitro potency and optimal in vivo efficacy, a conformationally constrained molecule was designed based on the highly potent and flexible 13. The synthetic chemistry efforts led to the discovery of

1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.